NEW YORK, Sept. 2, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that it has received a Phase II grant of approximately $3 million from the National Institutes of Health (NIH), to continue exploring the use of ST-246(r) as an adjunct to the current smallpox vaccine for prevention of smallpox vaccine-related adverse events.
